Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
1.240
-0.060 (-4.62%)
At close: Nov 13, 2026, 4:00 PM EST
1.257
+0.017 (1.37%)
After-hours: Nov 13, 2026, 7:30 PM EST
Alzamend Neuro Market Cap
Alzamend Neuro has a market cap or net worth of $5.98 million as of November 13, 2026. It is the 43,757th most valuable company in the world and the 5,789th biggest in the United States. Its market cap has decreased by 32.73% in one year.
Market Cap
5.98M
Enterprise Value
-1.61M
1-Year Change
-32.73%
Global Rank
Country Rank
#5,789 United States
Category
ChartMarket Cap Chart
Since the IPO on June 15, 2021, Alzamend Neuro's market cap has decreased from $1.15B to $5.98M, a decrease of -99.48%. That is a compound annual growth rate of -62.10%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 13, 2026 | 5.98M | -13.51% |
| Dec 31, 2025 | 6.92M | 9.79% |
| Dec 31, 2024 | 6.30M | -0.56% |
| Dec 29, 2023 | 6.34M | -88.37% |
| Dec 30, 2022 | 54.47M | -67.73% |
| Dec 31, 2021 | 168.82M | -85.28% |
| Jun 15, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| GT Biopharma | 7.15M |
| Theriva Biologics | 7.08M |
| Exicure | 7.07M |
| Ensysce Biosciences | 7.00M |
| Soligenix | 6.97M |
| Enveric Biosciences | 6.76M |
| FibroBiologics | 6.43M |
| Processa Pharmaceuticals | 6.27M |